In a groundbreaking presentation at the US Biophysical Society, Asep Medical Holdings Inc. unveiled how their innovative use of artificial intelligence (AI) is transforming the field of healthcare. Led by renowned CEO Dr. Bob Hancock, the company has developed new and improved treatments for biofilm infections, an issue that causes 65% of all infections worldwide.
Biofilms, which are communities of bacteria that infect surfaces, have proven extremely resistant to existing antibiotics. Despite the detrimental impact they have on global healthcare, there has been no FDA-approved treatment for these infections. Recognizing the urgent need for a solution, Asep Medical utilized AI, specifically neural network AI methods, to predict improved peptides with significantly higher activity against biofilms. By analyzing the company’s extensive stock of proprietary peptides, this technology has not only enhanced the peptides’ effectiveness against biofilms but also their ability to suppress inflammation, the primary pathology of these infections.
With the potential to replace current sub-optimal treatments, including physical removal and combinations of antibiotics, Asep’s peptides open doors to various markets impacted by biofilms. These markets include oral health (dental) care, wounds, and chronic rhinosinusitis. Asep’s first-generation product will be an oral irrigant/rinse designed to prevent biofilm infections in the oral cavity, which can lead to dental issues and erosion of teeth and dental implants.
But Asep’s utilization of AI doesn’t stop there. The company is also harnessing LASSO regression, another form of AI, in the development of the SepsetER blood-based gene expression test. This test, which is preparing to enter regulatory approval studies, aims to accurately identify sepsis onset by analyzing dysfunctional immune responses. By focusing on the expression of just six genes, this test has shown promising results in predicting sepsis and associated multi-organ failure in patients.
The significance of these advancements cannot be understated. Sepsis, a severe disease responsible for one in five deaths worldwide, poses a substantial risk to patients’ lives. Identifying sepsis as early as possible is crucial in initiating appropriate treatment and preventing further complications. Currently, no conventional assay exists that accurately predicts sepsis onset in the first hours after a patient’s hospital admission. Asep’s SepsetER test, however, has demonstrated the ability to predict sepsis development in an impressive 9 out of 10 patients in the ICU and 7 out of 10 patients in the emergency department.
Furthermore, Asep’s use of AI has simplified the complexity of sepsis, leading to the identification of different groups of patients known as endotypes. These endotypes exhibit major differences in their underlying immune defects, allowing for tailored precision treatments. By utilizing gene assays, Asep has achieved accuracy rates of 89-97% in assessing these endotypes, offering further hope for precision medicine in sepsis treatment.
The failure of antibiotics, the prevalence of recalcitrant biofilm infections, and the rise of antibiotic resistance represent significant challenges in healthcare today. Asep Medical Holdings Inc., however, is leading the charge in overcoming these obstacles through the power of AI. By harnessing the potential of antimicrobial peptides and employing advanced AI techniques, the company is revolutionizing the field of healthcare and striving to improve human health on a global scale.
Frequently Asked Questions (FAQ)
- How do biofilms affect healthcare?
- How is Asep using AI in their research?
- What are the potential applications of Asep’s research?
- Why is the use of AI significant in healthcare?
Biofilms are communities of bacteria that infect surfaces and are responsible for 65% of all infections. They are highly resistant to antibiotics and pose a significant challenge in healthcare, requiring new and improved treatments.
Asep Medical Holdings Inc. combines neural network AI methods and LASSO regression to enhance their understanding of biofilm infections and sepsis. These AI techniques allow for the prediction of improved peptides and the identification of gene expression patterns associated with sepsis development.
Asep’s research opens doors to various markets impacted by biofilms, including oral health care, wound care, and chronic rhinosinusitis. Additionally, their SepsetER test has the potential to accurately diagnose sepsis onset, enabling timely and appropriate treatment.
AI offers a new approach to complex medical problems. Its ability to analyze vast amounts of data allows for the identification of patterns, prediction of outcomes, and development of tailored treatments, ultimately improving patient care and outcomes.
Sources: asepmedical.com, sepset.ca
Frequently Asked Questions (FAQ)
- How do biofilms affect healthcare?
- How is Asep using AI in their research?
- What are the potential applications of Asep’s research?
- Why is the use of AI significant in healthcare?
Biofilms are communities of bacteria that infect surfaces and are responsible for 65% of all infections. They are highly resistant to antibiotics and pose a significant challenge in healthcare, requiring new and improved treatments.
Asep Medical Holdings Inc. combines neural network AI methods and LASSO regression to enhance their understanding of biofilm infections and sepsis. These AI techniques allow for the prediction of improved peptides and the identification of gene expression patterns associated with sepsis development.
Asep’s research opens doors to various markets impacted by biofilms, including oral health care, wound care, and chronic rhinosinusitis. Additionally, their SepsetER test has the potential to accurately diagnose sepsis onset, enabling timely and appropriate treatment.
AI offers a new approach to complex medical problems. Its ability to analyze vast amounts of data allows for the identification of patterns, prediction of outcomes, and development of tailored treatments, ultimately improving patient care and outcomes.
Sources: asepmedical.com, sepset.ca
The source of the article is from the blog motopaddock.nl